We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 21, 2020

Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 Inhibitors

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Report From the Veterans Health Administration Clinical Assessment, Reporting, and Tracking (CART) Program
Diabetes Obes Metab 2020 Sep 09;[EPub Ahead of Print], T Salahuddin, V Richardson, DM McNeal, K Henderson, PL Hess, S Raghavan, DR Saxon, JA Valle, SW Waldo, PM Ho, GG Schwartz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading